Leerink said Humana's investor day yesterday focused on addressing longer-term Medicare Advantage rate concerns. Leerink finds the stock very attractively valued and thinks the company will continue to grow earnings faster than most of its more diversified peers over the next two to three years. The firm keeps an Outperform rating on Humana.
- Investment & Company Information
- Medicare Advantage